Please login to the form below

Not currently logged in
Email:
Password:

ibrutinib

This page shows the latest ibrutinib news and features for those working in and with pharma, biotech and healthcare.

BeiGene gets speedy US review for lymphoma drug zanubrutinib

BeiGene gets speedy US review for lymphoma drug zanubrutinib

BeiGene is trying to position zanubrutinib as a rival to AbbVie/Johnson &Johnson’s well-established BTK inhibitor Imbruvica (ibrutinib), which is already approved for several haematological disorders – including CLL, MCL

Latest news

More from news
Approximately 17 fully matching, plus 74 partially matching documents found.

Latest Intelligence

  • Taking a strategic approach Taking a strategic approach

    In the case of blood cancer drug Imbruvica (ibrutinib) - a key new product for the company - Janssen has requested its single technology appraisal for CLL and MCL be rescheduled to start

  • Pharma deals during November 2014 Pharma deals during November 2014

    Whatever CAR-T's promise, for the time being of course the chronic lymphocytic leukaemia company to beat is Pharmacyclics with Imbruvic (ibrutinib), its oral small molecule still proving remarkably resilient ... Ibrutinib blocks signals that tell

  • Pharma deals during October 2014 Pharma deals during October 2014

    This clinical trial collaboration will look at a phase 1/2 study for Opdivo in combination with Imbruvica [ibrutinib – an oral Bruton's kinase inhibitor] as a treatment option for

  • Deal Watch table for July 2013 Deal Watch table for July 2013

    Quest Diagnostics / Royalty Pharma. Purchase of royalty rights. Ibrutinib (Bruton's tyrosine kinase inhibitor) for CLL and other B-cell cancers (p3).

  • Pharma deals during July 2013 Pharma deals during July 2013

    However, Royalty Pharma did close a deal this month with presumably a fully cooperative partner, Quest Diagnostics, which had deemed the phase III anticancer drug ibrutinib to be non-core and

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS Just::

HAVAS Just:: is a different kind of healthcare communications agency. Our mission is to create campaigns that make people think....

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics